Answer
Shkreli was fined $64.6 million in the antitrust civil case. This substantial penalty was imposed due to his involvement in anti-competitive practices, specifically conspiring to monopolize the market for the life-saving drug Daraprim. His actions resulted in a significant increase in the price of the medication, causing immense hardship for patients who relied on it.